G Enblad

Summary

Affiliation: Radiology and Clinical Immunology
Country: Sweden

Publications

  1. ncbi request reprint Lack of correlation between EBV serology and presence of EBV in the Hodgkin and Reed-Sternberg cells of patients with Hodgkin's disease
    G Enblad
    Department of Oncology, Uppsala University, Akademiska sjukhuset, Sweden
    Int J Cancer 72:394-7. 1997
  2. ncbi request reprint A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas
    Gunilla Enblad
    Department of Oncology, Uppsala University Hospital, Uppsala, Sweden
    Blood 103:2920-4. 2004
  3. ncbi request reprint Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease: a prospective study
    G Enblad
    Department of Oncology, Uppsala University Hospital, Sweden
    Eur J Haematol 60:166-71. 1998
  4. ncbi request reprint Epstein-Barr virus distribution in Hodgkin's disease in an unselected Swedish population
    G Enblad
    Department of Oncology, Uppsala University, Akademiska sjukhuset, Sweden
    Acta Oncol 38:425-9. 1999
  5. ncbi request reprint Patients above sixty years of age with Hodgkin's lymphoma treated with a new strategy
    Gunilla Enblad
    Department of Oncology, Radiology and Clinical Immunology, Uppsala University Hospital, Sweden
    Acta Oncol 41:659-67. 2002
  6. ncbi request reprint The potential role of innate immunity in the pathogenesis of Hodgkin's lymphoma
    Gunilla Enblad
    Department of Oncology, Radiology, and Clinical Immunology, Section of Oncology, Uppsala University Hospital, Rudbeck Laboratory C11, S 75185 Uppsala, Sweden
    Hematol Oncol Clin North Am 21:805-23. 2007
  7. ncbi request reprint Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma
    A Berglund
    Department of Oncology, Uppsala University, Akademiska sjukhuset, Sweden
    Eur J Haematol 65:17-22. 2000
  8. ncbi request reprint The serum levels of eosinophil cationic protein (ECP) are related to the infiltration of eosinophils in the tumours of patients with Hodgkin's disease
    D Molin
    Departments of Oncology, Radiology, and Clinical Immunology, Genetics and Pathology, University of Uppsala, University Hospital, Uppsala, Sweden
    Leuk Lymphoma 42:457-65. 2001
  9. ncbi request reprint Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for non-Hodgkin's lymphomas: a Swedish national prospective study. Swedish Lymphoma Study Group
    G Enblad
    Department of Oncology, Akademiska sjukhuset, Uppsala, Sweden
    Acta Oncol 35:165-70. 1996
  10. ncbi request reprint Treatment outcome in patients younger than 60 years with advanced stages (IIB-IV) of Hodgkin's disease: the Swedish National Health Care Programme experience
    R M Amini
    Department of Oncology, and Regional Oncological Centre, University Hospital in Uppsala, Sweden
    Eur J Haematol 65:379-89. 2000

Collaborators

Detail Information

Publications43

  1. ncbi request reprint Lack of correlation between EBV serology and presence of EBV in the Hodgkin and Reed-Sternberg cells of patients with Hodgkin's disease
    G Enblad
    Department of Oncology, Uppsala University, Akademiska sjukhuset, Sweden
    Int J Cancer 72:394-7. 1997
    ..The role of EBV in the development of HD, especially its relationship to the immunological response, remains unclear...
  2. ncbi request reprint A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas
    Gunilla Enblad
    Department of Oncology, Uppsala University Hospital, Uppsala, Sweden
    Blood 103:2920-4. 2004
    ..Further studies are warranted in younger patients and patients with less advanced disease...
  3. ncbi request reprint Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease: a prospective study
    G Enblad
    Department of Oncology, Uppsala University Hospital, Sweden
    Eur J Haematol 60:166-71. 1998
    ..We conclude that MIME induces remissions in a high proportion of patients with recurrent and refractory HD with acceptable toxicity. The remissions probably need consolidation, but the nature of this consolidation is still controversial...
  4. ncbi request reprint Epstein-Barr virus distribution in Hodgkin's disease in an unselected Swedish population
    G Enblad
    Department of Oncology, Uppsala University, Akademiska sjukhuset, Sweden
    Acta Oncol 38:425-9. 1999
    ..This could be explained by selection of patients from previous studies, or by differences in EBV-positivity in different geographical or ethnic populations of HD...
  5. ncbi request reprint Patients above sixty years of age with Hodgkin's lymphoma treated with a new strategy
    Gunilla Enblad
    Department of Oncology, Radiology and Clinical Immunology, Uppsala University Hospital, Sweden
    Acta Oncol 41:659-67. 2002
    ..Thus efforts to improve the chemotherapy regimen with individualized dosing did not change the outcome. Many patients experienced myelosuppression and opportunistic infections that may have contributed to the poor treatment results...
  6. ncbi request reprint The potential role of innate immunity in the pathogenesis of Hodgkin's lymphoma
    Gunilla Enblad
    Department of Oncology, Radiology, and Clinical Immunology, Section of Oncology, Uppsala University Hospital, Rudbeck Laboratory C11, S 75185 Uppsala, Sweden
    Hematol Oncol Clin North Am 21:805-23. 2007
    ..Mast cells and eosinophils seem also to contribute to the fibrosis that is so characteristic for nodular sclerosis...
  7. ncbi request reprint Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma
    A Berglund
    Department of Oncology, Uppsala University, Akademiska sjukhuset, Sweden
    Eur J Haematol 65:17-22. 2000
    ..In the absence of randomised trials the role of high-dose treatment for patients with follicular lymphoma is still not defined...
  8. ncbi request reprint The serum levels of eosinophil cationic protein (ECP) are related to the infiltration of eosinophils in the tumours of patients with Hodgkin's disease
    D Molin
    Departments of Oncology, Radiology, and Clinical Immunology, Genetics and Pathology, University of Uppsala, University Hospital, Uppsala, Sweden
    Leuk Lymphoma 42:457-65. 2001
    ..The same patients had a higher ESR and tended to have a more advanced stage and bulky disease. There are no significant correlations with disease-free and overall survival, as the follow-up time is short, and prognosis favourable...
  9. ncbi request reprint Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for non-Hodgkin's lymphomas: a Swedish national prospective study. Swedish Lymphoma Study Group
    G Enblad
    Department of Oncology, Akademiska sjukhuset, Uppsala, Sweden
    Acta Oncol 35:165-70. 1996
    ..The remissions are, however, generally of short duration and need consolidation. There was considerable toxicity therefore patients not suitable for ABMT preferably should be treated with less toxic salvage regimens...
  10. ncbi request reprint Treatment outcome in patients younger than 60 years with advanced stages (IIB-IV) of Hodgkin's disease: the Swedish National Health Care Programme experience
    R M Amini
    Department of Oncology, and Regional Oncological Centre, University Hospital in Uppsala, Sweden
    Eur J Haematol 65:379-89. 2000
    ..Secondly, we investigated if variables of prognostic importance could be detected...
  11. ncbi request reprint Infradiaphragmatic Hodgkin's disease: the Swedish National Care Programme experience. The Swedish Lymphoma Study Group
    K M Kalkner
    Department of Oncology, University of Uppsala, University Hospital, Sweden
    Eur J Haematol 59:31-7. 1997
    ....
  12. ncbi request reprint Bulky disease is the most important prognostic factor in Hodgkin lymphoma stage IIB
    Ingrid Glimelius
    Department of Oncology, Radiology, and Clinical Immunology, Rudbeck Laboratory, Uppsala University Hospital, Uppsala, Sweden
    Eur J Haematol 71:327-33. 2003
    ..In conclusion, we suggest that bulky disease should be taken into account when treating patients with stage IIB HL...
  13. ncbi request reprint Outcome for young high-risk aggressive B-cell lymphoma patients treated with CHOEP-14 and rituximab (R-CHOEP-14)
    Magdalena Adde
    Department of Oncology, Uppsala University Hospital, 751 85 Uppsala Sweden
    Med Oncol 23:283-93. 2006
    ..To study the effectiveness and tolerability of a dose-intensified treatment including rituximab for patients, not older than 65 yr, with high-risk aggressive B-cell lymphoma...
  14. ncbi request reprint A more favourable clinical course of lymphoma relapsing after high-dose therapy: evidence of tumour heterogeneity?
    G Enblad
    Departments of Oncology, Radiology and Clinical Immunology, Uppsala University, Akademiska sjukhuset, Uppsala, Sweden
    Med Oncol 17:229-32. 2000
    ..Possible explanations could be selection of less malignant clones or a lymphoma controlled by the immune system. The mechanisms are, however, unknown but warrant further studies of the molecular biology in these and similar cases...
  15. ncbi request reprint Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue
    Marie Fischer
    Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden
    Int J Cancer 107:197-201. 2003
    ..Taken together, our results suggest that CCL5 produced by HRS cells is one mechanism by which mast cells can be attracted into the tumor tissue in HL...
  16. ncbi request reprint Mast cell infiltration is a favourable prognostic factor in diffuse large B-cell lymphoma
    Gustaf Hedström
    Department of Oncology, Radiology and Clincial Immunology, Uppsala University, Uppsala, Sweden
    Br J Haematol 138:68-71. 2007
    ..03 in both germinal centre (GC) and non-GC DLBCL. This supports the idea that the infiltration of mast cells is a reflection of the host inflammatory response and is related to a favourable outcome...
  17. ncbi request reprint IL-9 expression contributes to the cellular composition in Hodgkin lymphoma
    Ingrid Glimelius
    Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden
    Eur J Haematol 76:278-83. 2006
    ..The aim of this study was to explore if the expression of IL-9 correlates to the presence of these inflammatory cells in HL tumours...
  18. ncbi request reprint Early and intermediate stage Hodgkin's lymphoma--report from the Swedish National Care Programme
    Daniel Molin
    Department of Oncology, Radiology, and Clinical Immunology, University Hospital, Uppsala, Sweden
    Eur J Haematol 70:172-80. 2003
    ..These results favour the trend to treat early and intermediate stages with a short course of chemotherapy followed by limited RT...
  19. ncbi request reprint Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma
    Daniel Molin
    Department of Oncology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Br J Haematol 119:122-4. 2002
    ..Mast cells were detected in virtually every case and increasing numbers of mast cells correlated to nodular sclerosis histology (P = 0.008). Patients with higher mast cell infiltration had a worse relapse-free survival (P = 0.01)...
  20. ncbi request reprint Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease
    D Molin
    Department of Genetics and Pathology, Uppsala University, University Hospital, Uppsala, Sweden
    Br J Haematol 114:616-23. 2001
    ..In conclusion, mast cells are present in HD tumours and are the predominant CD30L-expressing cells. CD30L-CD30 interaction is a pathway by which mast cells may stimulate DNA synthesis in HRS cells...
  21. ncbi request reprint Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-Cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4)
    H Hagberg
    Department of Oncology, Akademiska sjukhuset, Uppsala, Sweden
    Med Oncol 22:191-4. 2005
    ..No severe side effects were observed during the antibody treatment. This case report is the first describing that HuMax-CD4 has antilymphoma activity in PTL and is an interesting drug to study further in patients with CD4+ PTL...
  22. ncbi request reprint Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma
    M Fischer
    Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden
    Leukemia 17:2513-6. 2003
    ..A novel correlation between increased serum IL-9 levels, HL and clinical features is shown, suggesting that IL-9 is a candidate factor contributing to the development of HL...
  23. doi request reprint Cancer of the parotid gland; long-term follow-up. A single centre experience on recurrence and survival
    Lena Cederblad
    Department of Oncology, Radiology and Clinical Immunology, University Hospital, Uppsala, Sweden
    Acta Oncol 48:549-55. 2009
    ..The aim of the study was to investigate the results of treatment of malignant parotid gland tumours at a single centre during a 56 year period, focusing on tumour control and survival...
  24. ncbi request reprint A novel B-cell line (U-2932) established from a patient with diffuse large B-cell lymphoma following Hodgkin lymphoma
    Rose Marie Amini
    Department of Genetics and Pathology, Uppsala University, Uppsala University Hospital, SE 751 85 Uppsala, Sweden
    Leuk Lymphoma 43:2179-89. 2002
    ..This cell line may become a useful tool to better understand the mechanisms responsible for development of secondary NHL in patients treated for HL...
  25. ncbi request reprint Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis
    Eva Baecklund
    Department of Rheumatology, Akademiska Hospital, Uppsala, Sweden
    Arthritis Rheum 54:3774-81. 2006
    ..This study was undertaken to investigate whether RA displays a specific association with any of the DLBCL subtypes...
  26. ncbi request reprint Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis
    Mattias Berglund
    Department of Oncology, Radiology, and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Mod Pathol 18:1113-20. 2005
    ..Here we confirm the prognostic importance of determining the germinal- or nongerminal center phenotype in patients with DLBCL...
  27. doi request reprint Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis
    Eva Baecklund
    Department of Rheumatology, University Hospital, Uppsala, Sweden
    Br J Haematol 141:69-72. 2008
    ..This supports that a majority of RA-DLBCL are of non-GC origin, indicating a specific role for activated peripheral B cells in the pathogenesis of RA-DLBCL...
  28. doi request reprint Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma
    Johan Linderoth
    Department of Oncology, Lund University Hospital, Lund, Sweden
    Br J Haematol 141:423-32. 2008
    ..These findings indicate that a reactive microenvironment has an impact on the outcome of chemotherapy in DLBCL...
  29. ncbi request reprint Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma
    Sarah H Walsh
    Department of Genetics and Pathology, Uppsala University, Sweden
    Blood 101:4047-54. 2003
    ..03), but they tended to be younger at diagnosis. The combined use of V(H)3-21/V(lambda)3-19 suggests a possible role for antigen(s) in the pathogenesis of these tumors and indicates that V(H)3-21(+) patients constitute a new MCL entity...
  30. ncbi request reprint Relationship between Hodgkin's and non-Hodgkin's lymphomas
    Rose Marie Amini
    Department of Genetics and Pathology, Uppsala University, Uppsala University Hospital, Uppsala, Sweden
    Med Oncol 20:211-20. 2003
    ..It is thus possible that a biological relationship between the disorders may exist in addition to morphological overlaps, and the purpose with this review is to summarize the different relations between HL and NHL...
  31. doi request reprint TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype
    Norafiza Zainuddin
    Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden
    Leuk Res 33:60-6. 2009
    ..002 and PFS, P=0.006). Neither MDM2 SNP309 nor the TP53 codon 72 polymorphism had an impact on age of onset or survival. Altogether, our data suggests that TP53 mutations are associated with poor outcome in GC-DLBCL patients...
  32. ncbi request reprint Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia
    Gerard Tobin
    Department of Genetics and Pathology, Uppsala University, SE 751 85 Uppsala, Sweden
    Blood 99:2262-4. 2002
    ..We therefore suggest that B-CLL cases with mutated V(H)3-21 genes may constitute an additional entity of B-CLL...
  33. ncbi request reprint Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope
    Gerard Tobin
    Department of Genetics and Pathology, Uppsala University, Sweden
    Blood 101:4952-7. 2003
    ....
  34. ncbi request reprint Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy
    Heidi Nyman
    Department of Oncology, Helsinki University Central Hospital, FIN 00029 Helsinki, Finland
    Blood 109:4930-5. 2007
    ..030; FFS, 79% vs 52%, P = .028). We conclude that rituximab in combination with chemotherapy seems to eliminate the prognostic value of immunohistochemically defined GC- and non-GC phenotypes in DLBCL...
  35. ncbi request reprint A population-based study of the outcome for patients with first relapse of Hodgkin's lymphoma
    Rose Marie Amini
    Department of Oncology and Regional Oncological Centre, University Hospital of Uppsala, Sweden
    Eur J Haematol 68:225-32. 2002
    ..Our aims were to evaluate the response to salvage treatment in relation to initial treatment and to evaluate prognostic factors at the time of relapse in an unselected population of relapsing patients with Hodgkin's lymphoma (HL)...
  36. ncbi request reprint Relapsed Hodgkin's lymphoma: immunostaining patterns in relation to survival
    Rose Marie Amini
    Department of Genetics and Pathology, University of Uppsala, Sweden
    Leuk Lymphoma 43:1253-60. 2002
    ..We found a significant relation between the expression of p53 and EBV at diagnosis and relapse, indicating a clonal relationship. We were unable to find any specific staining pattern of p53 or Rb, affecting survival...
  37. ncbi request reprint Establishment of a cell line from a chemotherapy resistant diffuse large B-cell lymphoma
    Mattias Berglund
    Leuk Lymphoma 48:1038-41. 2007
  38. ncbi request reprint U-2940, a human B-cell line derived from a diffuse large cell lymphoma sequential to Hodgkin lymphoma
    Clara Sambade
    Institute for Molecular Pathology and Immunology, Porto University, Porto, Portugal
    Int J Cancer 118:555-63. 2006
    ....
  39. ncbi request reprint Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN
    Marie Fridberg
    Department of Tumor Biology, Lund University, Malmo University Hospital, Malmo, Sweden
    Leuk Lymphoma 48:2221-32. 2007
    ..For the first time, we show that ZAP70 is expressed in a higher percentage of tumor cells in the aggressive non-GC subgroup of DLBCL and that PKC-beta I and II are differently distributed in the two prognostic subgroups of de novo DLBCL...
  40. ncbi request reprint Clonal development of a blastoid mantle cell lymphoma studied with comparative genomic hybridization
    Emma Flordal
    Department of Molecular Medicine, Karolinska Hospital, SE 171 76, Stockholm, Sweden
    Cancer Genet Cytogenet 139:38-43. 2002
    ....
  41. ncbi request reprint Chromosomal imbalances in diffuse large B-cell lymphoma detected by comparative genomic hybridization
    Mattias Berglund
    Department of Molecular Medicine, Karolinska Hospital, Stockholm, Sweden
    Mod Pathol 15:807-16. 2002
    ....
  42. ncbi request reprint Molecular cytogenetic characterization of four commonly used cell lines derived from Hodgkin lymphoma
    Mattias Berglund
    Department of Molecular Medicine, CMM L8 01, Karolinska Hospital, SE 171 76, Stockholm, Sweden
    Cancer Genet Cytogenet 141:43-8. 2003
    ..Multiple numerical and structural abnormalities were identified in DEV and HDLM-2, as well as in L-540. Refined composed karyotypes are suggested for the cell lines studied, to be used as references for further studies of lymphoma...
  43. pmc Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion
    Marie Fischer
    Department of Medicine, Karolinska Institutet, Stockholm, Sweden
    J Clin Invest 116:2748-56. 2006
    ..These diseases include Hodgkin lymphoma, atopic dermatitis, and psoriasis...